OR WAIT null SECS
Extensive research on various gene editing techniques could inform the future of mRNA therapies.
In this excerpt from a recent episode of the Drug Soutions Podcast, Chris Spivey, editorial director, hosts a panel on advances in mRNA. In this clip, Chris, Kate Broderick, and Tom Madden discuss how extensive research is being conducted around various gene editing techniques and what that means for the future of mRNA. Other topics include epigenetic approaches to modulate gene expression, the expression of monoclonal antibodies, and protein replacement treatments.
For the complete discussion, check out the full podcast episode here.
Dr. Kate Broderick, chief innovation officer at Maravai LifeSciences has extensive experience and expertise in leading and liaising with multi-disciplinary groups from discovery and R&D to engineering and clinical teams. She brings strong and broad scientific expertise to TriLink Biotechnologies, which covers multiple areas, including gene delivery, medical devices, gene therapies for the treatment of various infectious diseases, cancer immunotherapies and vaccine development. Additionally, she has extensive experience with non-viral delivery systems for a wide range of vaccine targets and cancer immunotherapies.
Dr. Thomas D. Madden, president & CEO of Acuitas Therapeutics, is a world-renowned expert in the area of nanotechnology. Dr. Madden co-founded Acuitas Therapeutics in February 2009 and has guided the company into its position as a global leader through the development and application of lipid nanoparticle (LNP) technology. Acuitas Therapeutics partners with leading pharmaceutical and biotechnology companies and prestigious academic institutions around the world, providing its proprietary LNP delivery technology to enable new drugs based on nucleic acid therapeutics.
Pharmaceutical Technology presents the Drug Solutions podcast, where the editors will chat with industry experts from across the pharmaceutical and biopharmaceutical supply chain. Join us as experts share insights into your biggest questions—from the technologies, to strategies, to regulations related to the development and manufacture of drug products.